Login

CATALYST PHARMACEUTICALS, INC. 8-K SEC Filings

Filed On Filing
16 Jul 2026 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more

1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808.

08 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

30 Jun 2026 8-K: Other Events

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

23 Jun 2026 8-K: Other Events

As previously announced, on May 6, 2026, Catalyst Pharmaceuticals, Inc. (“Catalyst”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Angelini Pharma S.p.A., an Italian Società per azioni (“Angelini Pharma”), an...

11 May 2026 8-K: Other Events

Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE®

07 May 2026 8-K: Entry into a Material Definitive Agreement; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more

Form of Certificate of Incorporation of the Surviving Corporation

18 Mar 2026 8-K: Other Events

On March 18, 2026, the District Court for the District of New Jersey filed an order delaying the start of the bench trial between the Company and Hetero USA, Inc. from March 23, 2026 until May 18, 2026. The bench trial relates to the val...

25 Feb 2026 8-K: Other Events

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking

12 Jan 2026 8-K: Regulation FD Disclosure

NASDAQ: CPRX Improving the Lives of Patients Living with Rare Diseases January 2026 Exhibit 99.1

05 Nov 2025 8-K: Other Events

Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA®

01 Oct 2025 8-K: Other Events

CORAL GABLES, Fla., October 1, 2025 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for peopl...

25 Aug 2025 8-K: Other Events

CORAL GABLES, Fla., August 25, 2025- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patie...

07 Aug 2025 8-K: Other Events

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

06 Aug 2025 8-K: Other Events

Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth

04 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

CORAL GABLES, Fla. – Aug. 4, 2025 – Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors.

02 Jun 2025 8-K: Other Events

Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career

23 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

07 May 2025 8-K: Other Events

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook

09 Apr 2025 8-K: Other Events

Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

26 Feb 2025 8-K: Other Events

Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support